Urovant Sciences GmbH (Switzerland)

Urovant Sciences GmbH (Switzerland) is a Swiss-registered pharmaceutical company based in Basel, Switzerland, associated with the urology-focused specialty business of Sumitomo Pharma. It sits within the broader Sumitomo Pharma organization, whose U.S. operations were consolidated into Sumitomo Pharma America, Inc. (SMPA), a company formed by combining seven U.S. affiliate companies of Sumitomo Pharma. SMPA describes itself as a member of the Sumitomo Group, which it says has a 400-year history, and as building on the 100-year history of Sumitomo Pharma Group. Urovant's therapeutic focus is urology, one of the core areas SMPA lists alongside oncology, women's health, rare disease, CNS, and cell and gene therapies. The urology portfolio within SMPA includes Gemtesa (vibegron), a treatment for overactive bladder, which appears in SMPA's corporate transparency and pricing disclosure documents. Other SMPA products referenced in those documents include Myfembree (relugolix, estradiol, and norethindrone acetate), Orgovyx (relugolix), and Rethymic (allogeneic processed thymus tissue–agdc). The entity is registered in Switzerland, with Wikidata describing it simply as a company in Basel, Switzerland. It operates as part of a larger corporate group rather than as an independent public company, and its commercial activities are closely tied to the U.S. specialty pharmaceutical business of Sumitomo Pharma. Because public information specific to the Swiss legal entity is limited, the dossier draws primarily on the corporate context of its parent organization and the product portfolio it supports.

Urovant Sciences GmbH (Switzerland) is a Swiss-registered company based in Basel, Switzerland, according to Wikidata. It is associated with the urology specialty business of Sumitomo Pharma, a Japanese pharmaceutical group. Public information about the Swiss legal entity itself is sparse; the available evidence describes it primarily through its corporate affiliation and the product portfolio of the wider organization. Sumitomo Pharma's U.S. operations were consolidated into Sumitomo Pharma America, Inc. (SMPA), which was formed through the consolidation of Sumitomo Pharma's seven U.S. affiliate companies. SMPA states that it builds on the 100-year history of Sumitomo Pharma Group and is a member of the Sumitomo Group, which it describes as having a 400-year history. SMPA's therapeutic areas include oncology, women's health, urology, rare disease, CNS, and cell and gene therapies. Within this structure, Urovant represents the urology-focused specialty pharmaceutical activity. The urology portfolio includes Gemtesa (vibegron), which is referenced in SMPA's corporate transparency and pricing disclosure documents, alongside products such as Myfembree, Orgovyx, and Rethymic. These products are commercialized by SMPA in the United States, and the Swiss entity operates as part of the broader Sumitomo Pharma group rather than as an independent listed company. Because the entity is registered in Switzerland but its commercial focus is tied to the U.S. specialty business, its history is best understood as part of Sumitomo Pharma's international specialty pharmaceutical operations. No founding date, founder, or independent corporate milestones specific to the Swiss entity are provided in the available evidence.

Urology-focused specialty pharmaceutical entity within Sumitomo Pharma's U.S. and global organization.

• Gemtesa

  Vibegron, a treatment referenced in Sumitomo Pharma America's product portfolio and pricing disclosure documents.

• Myfembree

  Relugolix, estradiol, and norethindrone acetate, referenced in SMPA corporate documents.

• Orgovyx

  Relugolix, referenced in SMPA corporate documents.

• Rethymic

  Allogeneic processed thymus tissue–agdc, referenced in SMPA corporate documents.

• 2020-10-07

  Urovant and Sunovion announce vibegron co-promotion agreement[6]Urovant 与 Sunovion 宣布 vibegron 共同推广协议finanznachrichten.de

  Reported: 2020-10-07

  Urovant Sciences announced a five-year U.S. co-promotion agreement with Sunovion Pharmaceuticals to promote vibegron to primary care physicians and patients, contingent on FDA approval. Sunovion is to provide related sales and marketing activities through March 31, 2026.

• 2020-05-27

  Urovant appoints James Hindman to its board[7]Urovant任命James Hindman为董事会成员finanznachrichten.de

  Reported: 2020-05-27

  Urovant Sciences announced the appointment of James Hindman to its board of directors.

1. 1Innovation today, healthier tomorrows | Sumitomo Pharma America, Inc.us.sumitomo-pharma.com
2. 2Women's Health, Urology, CNS, Oncology, Rare Disease | Sumitomo Pharma America, Inc.us.sumitomo-pharma.com
3. 3United in Our Mission to Deliver Therapies Quicker | Sumitomo Pharma America, Inc.us.sumitomo-pharma.com
4. 4Corporate Transparency Documents | Sumitomo Pharma America, Inc.us.sumitomo-pharma.com
5. 5Urovant Sciences GmbH (Switzerland) - Wikidatawikidata.org
6. 6Urovant 与 Sunovion 宣布 vibegron 共同推广协议finanznachrichten.de
7. 7Urovant任命James Hindman为董事会成员finanznachrichten.de